Kelly (Nasdaq: KELYA, KELYB) connects talented people to companies in need of their skills in areas including Science, Engineering, Education, Office, Contact Center, Light Industrial, and more. We’re always thinking about what’s next in the evolving world of work, and we help people ditch the script on old ways of thinking and embrace the value of all workstyles in the workplace. We directly employ nearly 350,000 people around the world and connect thousands more with work through our global network of talent suppliers and partners in our outsourcing and consulting practice. Revenue in 2021 was $4.9 billion. Visit kellyservices.com and let us help with what’s next for you.
Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.
Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Portfolio Optimization. Continuing its strategic actions to optimize its operating model and unlock capital, Kelly has sold the Ayers Group, a division of KellyOCG, to Keystone Partners, a Silver Oak Services Partners LLC portfolio company. While financial terms were not disclosed, the transaction further allows the Company to focus resources on specialties where KellyOCG is well positioned to compete and win over the long term, in our view.
Ayers Group. A provider of outplacement, executive coaching, and leadership development solutions to employers, Ayers was acquired by Kelly in 2006 for $4.6 million, with another $1.3 million of potential earnouts. Ayers was generating about $10 million of revenue at the time and while Kelly does not break out Ayers’ current revenue contribution, various sources estimate current revenue in the $20 million range.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
In the ever-evolving world of investing, savvy investors are constantly on the hunt for opportunities that offer the potential for outsized returns. While large-cap companies often dominate the spotlight, it’s the micro-cap universe that harbors some of the most exciting and undiscovered investment prospects. With market capitalizations typically ranging from $50 million to $300 million, these pint-sized powerhouses can pack a punch for those willing to navigate their inherent risks and volatility. In this article, we’ll explore the top micro-cap sectors that astute investors should have on their radar.
Technology The technology sector has long been a breeding ground for micro-cap innovation, and the rise of artificial intelligence (AI) has added another compelling opportunity. From software-as-a-service (SaaS) companies revolutionizing business processes to cybersecurity firms safeguarding our digital lives, micro-caps in this space are at the forefront of disruption. As businesses embrace AI capabilities, micro-cap tech companies developing cutting-edge AI solutions could experience exponential growth, making them attractive targets for investors seeking outsized returns.
Healthcare and Biotech The healthcare and biotech sectors are teeming with micro-cap companies pursuing groundbreaking treatments and medical devices. While the risks are undoubtedly high, with many drug candidates failing to reach commercialization, the potential rewards for successful micro-cap biotech firms can be staggering. From gene therapies to novel diagnostic tools, these micro-caps could revolutionize patient care and generate substantial returns for early investors.
Natural Resources As the global demand for natural resources continues to surge, micro-cap companies in the mining, oil and gas, and agriculture sectors could present lucrative opportunities. Micro-cap mining firms with promising mineral deposits or innovative extraction technologies may capture significant value as commodity prices fluctuate. Similarly, micro-cap oil and gas companies leveraging cutting-edge drilling or fracking techniques could capitalize on energy market dynamics.
Manufacturing and Industrials The manufacturing and industrials sectors are ripe with micro-cap companies offering innovative solutions to enhance productivity, automate processes, and streamline operations. From advanced robotics and automation technologies to cutting-edge materials and components, these micro-caps could experience significant growth as manufacturers seek to gain a competitive edge.
Consumer and Retail: Riding the Wave of Disruption The consumer and retail sectors are breeding grounds for micro-cap disruptors challenging established brands and business models. From emerging consumer brands tapping into niche markets to e-commerce and subscription-based retailers reshaping the shopping experience, these micro-caps have the potential to capture significant market share and generate substantial returns.
Navigating the micro-cap universe requires a keen eye for potential, a appetite for risk, and unwavering patience. However, for investors willing to put in the effort and embrace a long-term mindset, the rewards can be substantial. By maintaining a diversified portfolio across these promising micro-cap sectors, conducting thorough due diligence, and staying attuned to emerging trends and catalysts, savvy investors can unearth hidden gems before they capture the spotlight. While the journey may be full of twists and turns, the ability to identify and capitalize on the next big thing can separate the micro-cap maestros from the masses. Embrace the thrill of the hunt, and let your passion for discovering untapped potential be your guide through the exciting realm of micro-cap investing.
In a much-needed respite for consumers and the economy, the latest U.S. inflation data showed pricing pressures eased significantly in May. The Consumer Price Index (CPI) remained flat month-over-month and rose just 3.3% annually, according to the Bureau of Labor Statistics report released Wednesday. Both measures came in below economist expectations, marking the lowest monthly headline CPI reading since July 2022.
The lower-than-expected inflation numbers were driven primarily by a decline in energy costs, led by a 3.6% monthly drop in gasoline prices. The overall energy index fell 2% from April to May after rising 1.1% the previous month. On an annual basis, energy prices climbed 3.7%.
Stripping out the volatile food and energy categories, so-called core CPI increased just 0.2% from April, the smallest monthly rise since June 2023. The annual core inflation rate ticked down to 3.4%, moderating from the prior month’s 3.5% gain.
The cooling inflation data arrives at a pivotal time for the Federal Reserve as policymakers weigh their next policy move. Central bank officials have repeatedly stressed their commitment to bringing inflation back down to the 2% target, even at the risk of slower economic growth. The latest CPI print strengthens the case for interest rate cuts in the coming months.
Financial markets reacted positively to the encouraging inflation signals, with the 10-year Treasury yield falling around 12 basis points as traders priced in higher odds of the Fed starting to cut rates as soon as September. According to futures pricing, markets now see a 69% chance of a rate cut at the central bank’s September meeting, up sharply from 53% before the CPI release.
While the overall inflation trajectory is encouraging, some underlying price pressures remain stubbornly high. The shelter index, which includes rents and owners’ equivalent rent, rose 0.4% on the month and is up a stubbornly high 5.4% from a year ago. Persistent shelter inflation has been one of the biggest drivers of elevated core inflation readings over the past year.
Economists expect the housing components of inflation to eventually moderate given the recent rise in rental vacancy rates and slowing home price appreciation. However, the timing of that slowdown remains highly uncertain, keeping a key pillar of inflation risk intact for the time being.
Beyond shelter costs, other indexes that posted monthly increases included medical care services, used vehicle prices, and tuition costs for higher education. In contrast, airline fares, prices for new cars and trucks, communication services fees, recreation expenses and apparel prices all declined from April to May.
Despite the positive inflation signals from the latest CPI report, Federal Reserve officials have cautioned that the path back to 2% price stability will likely encounter bumps along the way. Last week’s stronger-than-expected jobs report reinforced the central bank’s hawkish policy stance, with the labor market adding 272,000 positions in May versus expectations for 180,000. Wage growth also remained elevated at 4.1% annually.
With both low inflation and low unemployment now seemingly achievable, the Federal Reserve will need to carefully navigate its policy path to engineer a so-called “soft landing” without tipping the economy into recession. Many economists expect at least a couple of 25 basis point rate cuts by early 2024 if inflation continues cooling as expected.
For investors, the latest CPI data provides a much-needed burst of optimism into markets that have been weighed down by persistent inflation fears and looming recession risks over the past year. Lower consumer prices should provide some relief for corporate profit margins while also supporting spending among cost-conscious households. However, the key question is whether this downshift in inflation proves durable or merely a temporary reprieve.
The Fed’s ability to deftly manage the competing forces of lowering inflation while sustaining economic growth will be critical for shaping the trajectory of investment portfolios in the months ahead. Keep a close eye on forward inflation indicators like consumer expectations, global supply dynamics, and wage trends to gauge whether this cooling phase proves lasting or short-lived. The high-stakes inflation battle is far from over.
In the relentless battle for tech supremacy, Apple has reclaimed its throne, dethroning Microsoft as the world’s most valuable public company after unveiling an ambitious artificial intelligence roadmap. The iPhone maker’s market capitalization surged past $3.3 trillion on Wednesday, surpassing Microsoft’s $3.2 trillion valuation, as investors rallied behind Apple’s audacious AI vision.
For years, Apple had remained relatively muted about its artificial intelligence pursuits, even as rivals like Microsoft, Google, and OpenAI raced ahead with generative AI models and conversational assistants. However, the company’s silence was shattered at its Worldwide Developers Conference (WWDC) on Monday, where it unveiled “Apple Intelligence” – a sweeping initiative to infuse AI capabilities across its product ecosystem.
At the core of Apple’s AI strategy is a suite of generative AI features that will be deeply integrated into its software and hardware. From writing assistance in core apps like Mail and Notes to AI-powered image and emoji generation, Apple aims to make artificial intelligence a seamless part of its user experience. Crucially, many of these cutting-edge AI capabilities will be exclusive to the latest iPhone models, potentially driving a surge in device upgrades and sales – a phenomenon analysts are calling an “iPhone super cycle.”
But Apple’s ambitions extend far beyond consumer-facing features. The company also announced plans to integrate large language models developed by OpenAI, a company in which Microsoft is a major investor, into its products and services. This strategic partnership underscores the complex web of alliances and rivalries that are emerging in the AI race.
While Apple’s AI plans have garnered widespread enthusiasm, skeptics question whether the company’s walled garden approach can truly compete with the open ecosystems fostered by rivals like Microsoft and Google. Apple’s insistence on maintaining tight control over its platforms and data has long been a source of contention, and some analysts worry that this could hamper the company’s ability to develop cutting-edge AI models at scale.
Nevertheless, Apple’s AI announcement has sent shockwaves through the tech industry, reigniting the battle for market dominance and technological leadership. As the company leverages its vast resources, cutting-edge hardware, and loyal user base to integrate AI into its products, it is poised to reshape the tech landscape and solidify its position as a formidable force in the AI revolution.
The resurgence of Apple as the world’s most valuable company is a testament to the immense potential – and potential pitfalls – of artificial intelligence. While AI promises to revolutionize industries and reshape the way we live and work, it also raises complex ethical and societal questions that must be grappled with by tech giants and policymakers alike.
As the AI race intensifies, companies like Apple and Microsoft will not only be vying for market supremacy but also shouldering the responsibility of shaping the future of this transformative technology. From addressing issues of bias and privacy to navigating the ethical implications of AI, these tech titans will play a pivotal role in determining how this powerful technology is developed and deployed.
With its latest AI offensive, Apple has reasserted its position as a tech leader, but the battle for AI dominance is far from over. As the industry continues to evolve at a breakneck pace, the companies that can strike the right balance between innovation, ethics, and user trust will emerge as the true winners in this high-stakes race.
CHATHAM, N.J., June 12, 2024 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced it has entered into a placement agency agreement for the purchase and sale of 3,753,558 shares of its common stock (or pre-funded warrants in lieu thereof) at an offering price of $1.065 per share (or $1.064 per pre-funded warrant in lieu thereof). The closing of the public offering is expected to take place on or about June 13, 2024, subject to the satisfaction of customary closing conditions.
The gross proceeds of the offering will be approximately $4.0 million before deducting placement agent fees and other estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, including the preparation of the new drug application relating to its Tonmya™ product candidate in patients with fibromyalgia, and the satisfaction of any portion of its existing indebtedness.
Dawson James Securities, Inc. is acting as the sole placement agent for the offering.
This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-266982) previously filed with the U.S. Securities and Exchange Commission (the “SEC”). The offering will be made only by means of a prospectus supplement and accompanying base prospectus, as may be further supplemented by any free writing prospectus and/or pricing supplement that Tonix may file with the SEC. A preliminary prospectus supplement and accompanying prospectus describing the terms of the proposed offering have been filed with the SEC and are available on the SEC’s website located at http://www.sec.gov. Electronic copies of the preliminary prospectus supplement may be obtained from Dawson James Securities, Inc., 101 North Federal Highway, Suite 600, Boca Raton, FL 33432 or by telephone at (561) 391-5555, or by email at investmentbanking@dawsonjames.com. Before investing in this offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that Tonix has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about Tonix and such offering.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Tonix Pharmaceuticals Holding Corp.*
Tonix is a fully-integrated biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for Tonmya1, a product candidate for which two statistically significant Phase 3 studies have been completed for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction as well as fibromyalgia-type Long COVID. Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has Breakthrough Therapy designation. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.
*Tonix’s product development candidates are investigational new drugs or biologics and have not been approved for any indication.
1Tonmya™ is conditionally accepted by the U.S. Food and Drug Administration (FDA) as the tradename for TNX-102 SL for the management of fibromyalgia. Tonmya has not been approved for any indication.
Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.
This press release and further information about Tonix can be found at www.tonixpharma.com.
Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 including those relating to the completion of the public offering, the satisfaction of customary closing conditions, the intended use of proceeds from the public offering and other statements that are predictive in nature. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.
TROY, Mich., June 12, 2024 (GLOBE NEWSWIRE) — Kelly (Nasdaq: KELYA, KELYB), a leading global specialty talent solutions provider, has completed the sale of Ayers Group, a division of KellyOCG, to Keystone Partners, a Silver Oak Services Partners LLC portfolio company. Ayers Group provides outplacement, executive coaching, and leadership development solutions to employers across a wide range of industries. Terms of the sale were not disclosed.
The sale of Ayers Group sharpens KellyOCG’s focus on global recruitment process outsourcing (RPO) and managed service provider (MSP) solutions. The transaction also unlocks incremental capital to redeploy toward Kelly’s specialty strategy.
“The sale of Ayers Group marks another step forward on KellyOCG’s journey to become the leading provider of global RPO and MSP solutions, which are key pillars of our strategy to meet the buyer where they are in their journey to total talent management,” said Tammy Browning, president, KellyOCG. “This transaction reflects our commitment to directing resources to specialties where KellyOCG is well positioned to compete and win over the long term.”
The sale of Ayers Group is the latest in a series of strategic actions Kelly has executed to further optimize its operating model, unlock capital, and strengthen its competitive position in higher-margin, higher-growth specialties. These actions include selling its European staffing operations; monetizing non-core real estate holdings and businesses; unwinding Kelly’s cross-shareholding arrangement with Persol and reducing the company’s ownership interest in PersolKelly, its Asia-Pacific staffing joint venture; and selling its operations in Brazil and Russia.
About Kelly®
Kelly Services, Inc. (Nasdaq: KELYA, KELYB) helps companies recruit and manage skilled workers and helps job seekers find great work. Since inventing the staffing industry in 1946, we have become experts in the many industries and local and global markets we serve. With a network of suppliers and partners around the world, we connect more than 500,000 people with work every year. Our suite of outsourcing and consulting services ensures companies have the people they need, when and where they are needed most. Headquartered in Troy, Michigan, we empower businesses and individuals to access limitless opportunities in industries such as science, engineering, technology, education, manufacturing, retail, finance, and energy. Revenue in 2023 was $4.8 billion. Learn more at kellyservices.com.
About The Ayers Group
The Ayers Group, headquartered in New York City, has helped companies adapt to change through comprehensive human resources and organizational development solutions. Learn more at www.ayers.com.
About Keystone Partners
Founded in 1982, Keystone Partners is a leading outplacement, executive coaching and leadership development consulting firm headquartered in Boston, Massachusetts. Keystone offers a range of services designed to help individuals and organizations successfully navigate the complexities of career management and development.
Forward-Looking Statements
This release contains statements that are forward looking in nature and, accordingly, are subject to risks and uncertainties. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about Kelly’s financial expectations, are forward-looking statements. Factors that could cause actual results to differ materially from those contained in this release include, but are not limited to, (i) changing market and economic conditions, (ii) disruption in the labor market and weakened demand for human capital resulting from technological advances, loss of large corporate customers and government contractor requirements, (iii) the impact of laws and regulations (including federal, state and international tax laws), (iv) unexpected changes in claim trends on workers’ compensation, unemployment, disability and medical benefit plans, (v) litigation and other legal liabilities (including tax liabilities) in excess of our estimates, (vi) our ability to achieve our business’s anticipated growth strategies, (vi) our future business development, results of operations and financial condition, (vii) damage to our brands, (viii) dependency on third parties for the execution of critical functions, (ix) conducting business in foreign countries, including foreign currency fluctuations, (x) availability of temporary workers with appropriate skills required by customers, (xi) cyberattacks or other breaches of network or information technology security, and (xii) other risks, uncertainties and factors discussed in this release and in the Company’s filings with the Securities and Exchange Commission. In some cases, forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. All information provided in this press release is as of the date of this press release and we undertake no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company’s expectations.
The GEO Group, Inc. (NYSE: GEO) is a leading diversified government service provider, specializing in design, financing, development, and support services for secure facilities, processing centers, and community reentry centers in the United States, Australia, South Africa, and the United Kingdom. GEO’s diversified services include enhanced in-custody rehabilitation and post-release support through the award-winning GEO Continuum of Care®, secure transportation, electronic monitoring, community-based programs, and correctional health and mental health care. GEO’s worldwide operations include the ownership and/or delivery of support services for 103 facilities totaling approximately 83,000 beds, including idle facilities and projects under development, with a workforce of up to approximately 18,000 employees.
Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.
Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
More Available Funding. ICE’s termination of competitor CoreCivic’s South Texas contract (see our report on CoreCivic) will provide funding for additional beds. According to ICE, “Closing this facility will enable ICE to reallocate funding to increase the overall detention bed capacity across the system by an estimated 1,600 beds to better support operational needs. This additional bedspace is being pursued across the country and is expected to be available immediately.”
The Opportunity. First, we expect some portion of the nearly 1,600 detainees at South Texas may need to be re-homed. Second, as noted, the freed up funding will increase overall detention bed capacity by 1,600 beds. The Agency stated, “Today’s announcement will provide an overall increase in bedspace and operate at or above the FY24 appropriated 41,500 minimum bed requirement…” With the current detainee population just over 37,300, ICE could now access nearly 6,000 more beds. GEO has ample capacity, both at existing and idled facilities, to assist ICE.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Euroseas Ltd. was formed on May 5, 2005 under the laws of the Republic of the Marshall Islands to consolidate the ship owning interests of the Pittas family of Athens, Greece, which has been in the shipping business over the past 140 years. Euroseas trades on the NASDAQ Capital Market under the ticker ESEA. Euroseas operates in the container shipping market. Euroseas’ operations are managed by Eurobulk Ltd., an ISO 9001:2008 and ISO 14001:2004 certified affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. Euroseas employs its vessels on spot and period charters and through pool arrangements.
Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
New time charter contract. Euroseas Ltd. executed a time charter contract for M/V Stephania K at a gross daily rate of $22,000 for a minimum period of 23 months to a maximum period of 25 months at the option of the charterer. The M/V Stephania K is a newbuild 1,800 twenty-foot equivalent unit (TEU) feeder container ship. Recall that TEU is a unit of cargo capacity that is based on the volume of a 20-foot-long intermodal container that can be transferred between different carriers. The new charter will commence upon delivery of the vessel from the shipyard which is expected to take place on June 28.
Favorable charter rate. The charter is expected to contribute EBITDA of roughly $11.0 million for the minimum contracted period and improves Euroseas’ remaining 2024 charter coverage to 90%. Based on the rate and duration, the charter represents a significant improvement compared to its sister vessel, the M/V Monica, which was recently chartered for 12 months at a rate of $16,000 per day.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
CoreCivic is a diversified, government-solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. We provide a broad range of solutions to government partners that serve the public good through high-quality corrections and detention management, a network of residential and non-residential alternatives to incarceration to help address America’s recidivism crisis, and government real estate solutions. We are the nation’s largest owner of partnership correctional, detention and residential reentry facilities, and believe we are the largest private owner of real estate used by government agencies in the United States. We have been a flexible and dependable partner for government for nearly 40 years. Our employees are driven by a deep sense of service, high standards of professionalism and a responsibility to help government better the public good. Learn more at www.corecivic.com.
Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.
Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
South Texas. ICE has informed CoreCivic of its intention to terminate the existing agreement for use of the South Texas Family Residential Center effective August 9th. This is a major blow, at least in the short-term, to CoreCivic. We are lowering our rating to Market Perform from Outperform as a result until the smoke clears.
Financial Impact. The 2,400 bed South Texas is CoreCivic’s most important contract, in our opinion. In 2023, the facility generated over 8% of overall revenue. Management estimates the annualized EPS impact to be a reduction of $0.38-$0.41 due to the closure. The Company has suspended its 2024 financial guidance. Facility population as of June 9th was 1,561.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Imagine a world where diseases are detected at the earliest stages, new life-saving drugs are developed in a fraction of the time, and medical resources are optimized to deliver the best possible care. This future may not be as far-fetched as it sounds, thanks to a revolutionary technology called quantum computing.
What is Quantum Computing? Quantum computing is a mind-bending technology that harnesses the strange behavior of particles at the subatomic level. Unlike traditional computers that process information as binary bits (0s and 1s), quantum computers use quantum bits or qubits that can exist in multiple states simultaneously. This superposition phenomenon allows quantum computers to perform millions of calculations at once, making them exponentially more powerful than classical computers.
The Healthcare Revolution While quantum computing may seem like something straight out of a science fiction movie, its potential applications in healthcare are very real and could transform the industry as we know it.
Accelerating Drug Discovery One of the most promising applications of quantum computing is in the field of drug discovery. Finding new medicines is a painstakingly slow and expensive process, often taking decades and billions of dollars. Quantum computers can simulate complex molecular interactions at an unprecedented scale, allowing researchers to quickly identify promising drug candidates. This could dramatically shorten the drug development timeline, saving lives and billions of dollars.
Consider this: It takes an average of 10 years and $2.6 billion to develop a new drug from initial discovery to market approval. With quantum computing, pharmaceutical companies could potentially cut development times by years, significantly reducing costs and getting life-saving treatments to patients faster.
Personalized Medicine We all have unique genetic makeups that influence our response to different treatments. Personalized medicine aims to tailor therapies to an individual’s genetic profile, but analyzing vast amounts of genomic data is a daunting task for classical computers. Quantum computers can process and identify patterns in complex genetic data, enabling truly personalized treatment plans that maximize efficacy and minimize side effects.
Imagine a future where your doctor can analyze your entire genome and prescribe a medication tailored specifically to your genetic makeup, minimizing the risk of adverse reactions or ineffective treatments. This level of precision could revolutionize healthcare, improving outcomes and reducing waste.
Enhanced Medical Imaging Medical imaging techniques like MRI and CT scans generate massive amounts of data. Quantum computing can enhance image processing, improving clarity and resolution, enabling earlier detection of diseases like cancer. Early detection is key to successful treatment and could save countless lives.
With quantum-enhanced imaging, doctors could potentially identify tumors and other abnormalities at much earlier stages, significantly increasing the chances of successful treatment and survival.
Optimized Healthcare Logistics Healthcare systems involve intricate logistics, from managing hospital resources to optimizing patient care. Quantum computing’s ability to solve complex optimization problems can help hospitals better manage staff, equipment, and patient flow, leading to improved efficiency and reduced costs.
By optimizing resource allocation and patient flow, quantum computing could help hospitals reduce wait times, improve patient experiences, and ultimately deliver better care at lower costs.
The Investment Opportunity While quantum computing is still in its early stages, the potential payoffs in healthcare are staggering. Tech giants like IBM, Google, and startups like Rigetti Computing are investing heavily in quantum research. As the technology matures, we can expect to see a surge of investment opportunities in quantum computing companies and healthcare firms that leverage this technology.
Analysts estimate that quantum computing could create a $450 billion to $850 billion annual market by 2045, with healthcare being one of the prime beneficiaries. Early investors in this space could see massive returns as the technology takes off.
Of course, there are challenges to overcome, such as building stable, large-scale quantum computers and developing algorithms tailored for healthcare applications. However, the potential rewards are vast, both in terms of human lives saved and financial returns for savvy investors who recognize the transformative power of quantum computing in healthcare.
Quantum computing holds the promise to revolutionize healthcare by accelerating drug discovery, enabling personalized medicine, enhancing medical imaging, and optimizing resource management. While the technology is still in its early stages, the potential benefits for medicine are enormous. As we continue to explore and develop quantum computing, the future of healthcare looks brighter than ever, offering new hope for patients and medical professionals alike.
BEIJING, June 11, 2024 (GLOBE NEWSWIRE) — QuantaSing Group Limited (NASDAQ: QSG) (“QuantaSing” or the “Company”), a leading online learning service provider in China, today announced that its board of directors (the “Board”) has authorized a share repurchase program under which the Company may repurchase up to US$20.0 million of its Class A ordinary shares in the form of American depositary shares (“ADSs”) during a twelve-month period commencing on June 11, 2024 (the “Share Repurchase Program”).
“The Share Repurchase Program is well-aligned with our commitment to maximizing value for our shareholders and reflects the Board’s confidence in the Company’s continued growth and long-term prospects,” said Mr. Peng Li, QuantaSing’s Chairman and Chief Executive Officer.
Repurchases under the program may be made from time to time through open market transactions at prevailing market prices, in privately negotiated transactions, in block trades and/or through other legally permissible means. The repurchases will be subject to all applicable rules and regulations, including Rule 10b-18 and Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, as well as the Company’s insider trading policy. The number of ADSs repurchased and the timing of repurchases will also depend on a number of factors, including, but not limited to, price, trading volume and general market conditions, along with the Company’s working capital requirements, general business conditions and other factors. The Board will review the Share Repurchase Program periodically, and may authorize adjustment of its terms and size or suspend or discontinue the program. The Company plans to fund the repurchases from its existing cash balance.
Safe Harbor Statements
This announcement contains forward-looking statements within the meaning of Section 27A of Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended and the Private Securities Litigation Reform Act of 1955. All statements other than statements of historical or current fact included in this press release are forward-looking statements, including but not limited to statements regarding QuantaSing’s financial outlook, beliefs and expectations. These statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “potential,” “continue,” “ongoing,” “targets,” “guidance” and similar statements. Among other things, the Financial Outlook in this announcement contains forward-looking statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases, and other written materials and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the Company’s growth strategies; its future business development, results of operations and financial condition; its ability to attract and retain new users and learners and to increase the spending and revenues generated from users and learners; its ability to maintain and enhance the recognition and reputation of its brand; its expectations regarding demand for and market acceptance of its services and products; trends and competition in China’s adult learning market; changes in its revenues and certain cost or expense items; the expected growth of China’s adult learning market; PRC governmental policies and regulations relating to the Company’s business and industry, general economic and political conditions in China and globally, and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks, uncertainties, or factors is included in the Company’s filings with the SEC, including, without limitation, the final prospectus related to the IPO filed with the SEC dated January 24, 2023. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
About QuantaSing Group Limited
QuantaSing is a leading online service provider in China dedicated to improving people’s quality of life and well-being by providing lifelong personal learning and development opportunities. The Company is the largest service provider in China’s online adult learning market and China’s adult personal interest learning market in terms of revenue, according to a report by Frost & Sullivan based on data from 2022. By leveraging its proprietary tools and technology, QuantaSing offers easy-to-understand, affordable, and accessible online courses to adult learners, empowering users to pursue personal development. Leveraging its extensive experience in individual online learning services and its robust technology infrastructure, the Company has expanded its services to corporate clients, and diversified its operations into its e-commerce business and its AI and technology business.
CHATHAM, N.J., June 11, 2024 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced that it intends to offer and sell shares of its common stock (or pre-funded warrants in lieu thereof). All of the securities to be sold in the offering are to be offered by Tonix. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, including the preparation of the new drug application relating to its Tonmya™ product candidate in patients with fibromyalgia, and the satisfaction of any portion of its existing indebtedness.
Dawson James Securities, Inc. is the sole placement agent for the offering.
This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-266982) previously filed with the U.S. Securities and Exchange Commission (the “SEC”). The offering will be made only by means of a prospectus supplement and accompanying prospectus. The preliminary prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Electronic copies of the preliminary prospectus supplement may be obtained, when available, from Dawson James Securities, Inc., 101 North Federal Highway, Suite 600, Boca Raton, FL 33432 or by telephone at (561) 391-5555, or by email at investmentbanking@dawsonjames.com. Before investing in this offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that Tonix has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about Tonix and such offering.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Tonix Pharmaceuticals Holding Corp.*
Tonix is a fully-integrated biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for Tonmya1, a product candidate for which two statistically significant Phase 3 studies have been completed for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction as well as fibromyalgia-type Long COVID. Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has Breakthrough Therapy designation. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.
*Tonix’s product development candidates are investigational new drugs or biologics and have not been approved for any indication.
1Tonmya™ is conditionally accepted by the U.S. Food and Drug Administration (FDA) as the tradename for TNX-102 SL for the management of fibromyalgia. Tonmya has not been approved for any indication.
Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.
This press release and further information about Tonix can be found at www.tonixpharma.com.
Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.
As the world races towards a greener future, a new frontier has emerged in the metals and mining industry – the race to secure rare earth metals. These vital elements, with names like neodymium, dysprosium, and terbium, are the unsung heroes of the clean energy revolution, essential for everything from electric vehicle motors to wind turbines and rechargeable batteries.
And a recent game-changing discovery by Norwegian mining firm Rare Earths Norway could shake up the investment landscape in this lucrative sector.
Europe’s Rare Earth Jackpot In early June 2024, Rare Earths Norway announced the discovery of Europe’s largest proven deposit of rare earth elements in the Fen Carbonatite Complex, located in southeastern Norway. With an estimated 8.8 million metric tons of total rare earth oxides (TREOs), including a staggering 1.5 million metric tons of magnet-related rare earths, this find is a potential goldmine for savvy investors.
What makes this discovery so significant is that it represents one of the few major rare earth deposits not owned or controlled by China, which currently dominates the global supply chain. As the world’s manufacturing powerhouse, China accounts for a whopping 70% of global rare earth ore extraction and 90% of rare earth ore processing.
This reliance on China has raised concerns about supply chain vulnerabilities and geopolitical risks, prompting a global race to secure alternative sources of these critical minerals.
The European Union’s Critical Raw Materials Act aims to extract at least 10% of the bloc’s annual rare earth demand by 2030, and the Norwegian deposit could be a game-changer in achieving this goal.
The Clean Energy Metals Boom The demand for rare earth metals is expected to skyrocket in the coming years as the clean energy transition gathers momentum. The International Energy Agency (IEA) has warned that today’s supply falls short of what is needed to transform the energy sector, highlighting the need for increased exploration and production.
Electric vehicles (EVs) and wind turbines are among the biggest drivers of rare earth demand. Neodymium, for instance, is a key component in the powerful permanent magnets used in EV motors and wind turbine generators. As the global EV market continues its rapid growth, with sales expected to surge from 6.6 million in 2022 to 26 million by 2030, according to BloombergNEF, the demand for these critical minerals will only intensify.
Investment Opportunities Abound The discovery of Europe’s largest rare earth deposit presents a multitude of investment opportunities for those willing to bet on the metals and mining sector’s transition to cleaner and more sustainable practices.
Rare Earths Norway itself could be a prime target for investors looking to get in on the ground floor. As the company works towards developing the first stage of mining by 2030, its stock could see significant upside potential as progress unfolds.
Beyond direct investment in mining companies, ancillary industries like mineral processing, refining, and specialized equipment manufacturing could also benefit from the rare earth metals boom.
Furthermore, companies focused on recycling and reclaiming rare earth materials from end-of-life products could play a crucial role in addressing supply shortages and reducing environmental impact.
Risks and Challenges Of course, investing in the metals and mining sector is not without its risks. Fluctuating commodity prices, geopolitical tensions, environmental concerns, and regulatory challenges are all factors that investors must carefully consider.
Additionally, developing a rare earth mine is a capital-intensive and time-consuming process, with significant upfront costs and potential delays.
However, for investors with a long-term perspective and a keen eye for emerging trends, the rare earth metals rush could present a unique opportunity to capitalize on the clean energy revolution’s insatiable appetite for these critical materials.
As the world transitions towards a more sustainable future, those who recognize the value of these unsung heroes – the rare earth metals – could be well-positioned to reap substantial rewards.
